NEM Laboratories Pvt Ltd Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: NEM Laboratories Pvt Ltd Pharmaceutical Export Portfolio Dataset — 2 Products, $168.7K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

NEM Laboratories Pvt Ltd — Pharmaceutical Exporter Profile (2026) | 2 Products, $168.7K Trade | TransData Nexus

NEM Laboratories Pvt Ltd

Indian Pharmaceutical Exporter · CNS & Psychiatric Specialist · $168.7K Total Trade · DGFT Verified

NEM Laboratories Pvt Ltd is an Indian pharmaceutical exporter with a total trade value of $168.7K across 2 products in 2 therapeutic categories. Based on 35 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Diazepam ($129.9K), Digoxin ($38.8K), .

NEM Laboratories Pvt Ltd — Export Portfolio & Destination Treemap

NEM Laboratories Pvt Ltd pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is NEM Laboratories Pvt Ltd? — Company Overview & Market Position

NEM Laboratories Pvt Ltd, established on December 20, 1984, is a private pharmaceutical company headquartered in Thane, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74999MH1984PTC034856. As of the latest available data, NEM Laboratories has an authorized capital of ₹1.60 crore and a paid-up capital of ₹1.55 crore. The company employs approximately 62 professionals. Its product portfolio includes a range of pharmaceutical formulations such as tablets, capsules, syrups, and injections, with a focus on therapeutic areas like Central Nervous System (CNS) and Psychiatric disorders, as well as Cardiovascular conditions.

What Does NEM Laboratories Pvt Ltd Export? — Product Portfolio Analysis

Top Products by Export Value

1Diazepam$129.9K 2Digoxin$38.8K

NEM Laboratories Pvt Ltd Therapeutic Categories — 2 Specializations

Product Portfolio — Top 2 by Export Value

NEM Laboratories Pvt Ltd exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Diazepam	CNS & Psychiatric	$129.9K	23	1.7%	9
2	Digoxin	Cardiovascular	$38.8K	12	1.8%	9

NEM Laboratories Pvt Ltd exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $168.7K. The top category is CNS & Psychiatric (77.0% of portfolio), followed by Cardiovascular (23.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

NEM Laboratories Pvt Ltd — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

NEM Laboratories operates its manufacturing facility at Plot No. 133, Krishna Industrial Estate, Navghar, Vasai Road (E), Thane, Maharashtra, 401210, India. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the facility is equipped to handle a diverse range of pharmaceutical products, catering to both domestic and international markets.

3Key Leadership

The leadership team at NEM Laboratories Pvt Ltd comprises:

Lalit Surendra Talati: Director since December 20, 1984.
Dhaval Ajay Talati: Director since March 20, 2004.
Mukti Jain: Director since February 16, 2010.
Siddhi Sunil Gandhi: Director since October 1, 2008.

These individuals have been instrumental in steering the company's strategic direction and operational growth.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does NEM Laboratories Pvt Ltd Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

NEM Laboratories Pvt Ltd's export activities, as per TransData Nexus proprietary trade data, include a total export value of $169,000 USD across 35 shipments, with products spanning two therapeutic categories. The top two exported products are Diazepam ($130,000, Rank #9, 1.7% market share) and Digoxin ($39,000, Rank #9, 1.8% market share). The primary therapeutic categories are CNS & Psychiatric (77.0%) and Cardiovascular (23.0%). However, specific regulatory approvals or market access statuses in the US, EU, UK, Australia, and Japan are not publicly available. The company's portfolio concentration is high, with the top five products accounting for 100% of exports, indicating a focused market strategy.

2Emerging Markets

NEM Laboratories Pvt Ltd's export data indicates a presence in emerging markets, with a significant focus on CNS & Psychiatric products (77.0%) and Cardiovascular products (23.0%). While specific details regarding WHO prequalification or market penetration in Africa, Latin America, and Southeast Asia are not publicly available, the company's export activities suggest an expanding footprint in these regions.

3Geographic Strategy

NEM Laboratories Pvt Ltd — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding NEM Laboratories Pvt Ltd's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not provide insights into its regulatory standing with the FDA.

2WHO & EU GMP

Information regarding NEM Laboratories Pvt Ltd's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's export data does not indicate compliance with these international standards.

3CDSCO & Indian Regulatory

NEM Laboratories Pvt Ltd holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, as indicated by its active status and compliance with Indian regulatory requirements. Specific details regarding export No Objection Certificates (NOCs) are not publicly available.

NEM Laboratories Pvt Ltd — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

NEM Laboratories Pvt Ltd operates in the pharmaceutical industry, focusing on CNS & Psychiatric and Cardiovascular products. While specific competitors in overlapping categories are not identified, the company's export data suggests a competitive presence in these therapeutic areas. A detailed market share comparison and head-to-head analysis would require access to proprietary market research data.

2Key Differentiators

NEM Laboratories Pvt Ltd's key differentiators include a focused product portfolio in CNS & Psychiatric and Cardiovascular therapeutic areas, with a high concentration of exports in these segments. The company's long-standing presence in the pharmaceutical industry since 1984 and its manufacturing capabilities in various dosage forms such as tablets, capsules, syrups, and injections further distinguish it in the market.

3Strategic Position

NEM Laboratories Pvt Ltd's current strategic direction appears to be centered on the production and export of generic pharmaceutical formulations, particularly in the CNS & Psychiatric and Cardiovascular segments. The company's export data indicates a focused approach, with the top five products accounting for 100% of exports. Future outlook would depend on market dynamics, regulatory developments, and the company's ability to diversify its product portfolio and geographic reach.

Buyer Due Diligence Brief — Evaluating NEM Laboratories Pvt Ltd as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

NEM Laboratories Pvt Ltd has a track record of exporting pharmaceutical products, with a total export value of $169,000 USD across 35 shipments. The company's export data indicates consistency in its export activities, with a focused product portfolio. Reliability indicators such as on-time delivery, product quality, and compliance with international standards are not publicly available.

2Certifications to Verify

Importers should verify the following certifications when considering NEM Laboratories Pvt Ltd as a supplier:

FDA Facility Registration: To confirm compliance with US FDA regulations.
WHO-GMP Certification: To ensure adherence to World Health Organization Good Manufacturing Practices.
EU GMP Certification: To verify compliance with European Union Good Manufacturing Practices.

Frequently Asked Questions — NEM Laboratories Pvt Ltd

How many pharmaceutical products does NEM Laboratories Pvt Ltd export from India?

NEM Laboratories Pvt Ltd exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Diazepam ($129.9K), Digoxin ($38.8K). Total export value is $168.7K.

What is NEM Laboratories Pvt Ltd's total pharmaceutical export value?

NEM Laboratories Pvt Ltd's total pharmaceutical export value is $168.7K, based on 35 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does NEM Laboratories Pvt Ltd cover?

NEM Laboratories Pvt Ltd exports across 2 therapeutic categories. The largest are CNS & Psychiatric (77.0%, 1 products), Cardiovascular (23.0%, 1 products).

Get Full NEM Laboratories Pvt Ltd Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.